🏢 公司NewsroomKURADoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 09-04(美东日)仅日期·⟳ 抓取 09-05 22:16:05回填·⚡ 决策 09-12 11:58:16·45.5 天前
Kura Oncology 依 Nasdaq 规则向4名新员工授予48,450份诱导期权，属常规薪酬合规披露
这是Nasdaq上市公司针对新员工的标准诱导性期权合规披露（Rule 5635(c)(4)），规模仅48,450股、名义价值约62万美元，不含经营、管线、商业化（KOMZIFTI销售）、融资或控制权增量信息，无预期差与交易edge。
📄 原文KURA↗ 原文
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical…
不做 Kura Oncology, Inc.（KURA.US）
常规Nasdaq 5635(c)(4)诱导期权授予：仅48,450份、名义约62万美元、四年服务归属，无经营/管线/销售/资本结构增量信息，无预期差与交易edge；不做多也不构成做空理由。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实链：公司IR经GlobeNewswire公告向4名新员工授予48,450份诱导期权，行权价等于授予日收盘价12.89美元，按标准四年归属。此类披露是入职薪酬安排的法定豁免公告，数量占公司股本比例极低（不足0.05%量级），既不改变每股权益的实质（微小常规稀释已在薪酬计划框架内），也不包含KOMZIFTI商业化或管线进展信号；属典型无增量事实的常规披露，不产生方向性交易机会，故AVOID。
🔎 新鲜度:最早出现 2026-09-04 · 扩散 low · price-in 风险 low ↗
主要风险
- 信息为公司官方一手披露但天然偏正面叙事；本事件本身无风险，公司个股仍受KOMZIFTI销售放量、AML竞争及临床数据等独立因素影响，与本公告无关。
反向证据
- 做多前查反向 · 来源 web · 影响 none
本公告未夹带任何管线、销售指引或合作信息；4名新员工入职属于正常人员补充，不推断为扩张信号
检索:Kura Oncology 2026年9月 管线 KOMZIFTI ziftomenib 销售 临床 重大进展 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认AVOID，未产生任何ENTER参数
方向:无可比交易先例；常规诱导期权授予在美股生物科技板块每周均有大量同类披露，历史上不构成股价驱动事件，故无需回测面板
涨幅量级:不适用——无基本面增量，不用任何先例校准幅度
形态:此类Rule 5635(c)(4)模板公告通常无价格反应
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 42 ms
{"result": "search_processed_events:agent query=`kura new employee stock option grant september 2026 | kura oncology inducement grants nasdaq 5635(c)(4) stock options 48450 shares`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 28.2/72 小时、359 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"
原文全文
展开原文 · 2,187 字
SAN DIEGO
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
September 1, 2026
, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
$12.89
per share, the closing price of the Company’s common stock on
September 1, 2026
, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI
®
(ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
LinkedIn
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
,
Sept. 04, 2026
(GLOBE NEWSWIRE) --
Kura Oncology, Inc.
(the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
September 1, 2026
, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
$12.89
per share, the closing price of the Company’s common stock on
September 1, 2026
, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI
®
(ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory
NPM1
-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at
https://kuraoncology.com/
and follow us on
X
and
.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。